Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients with central serous chorioretinopathy (CSC) will be monitored with laser speckle flow graphy (LSFG), swept source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA). The aim is to unveil the flow and pulse wave characteristics of the choroidal circulation in acute CSC and chronic CSC.
Acute CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics are related to the eventual resolution of subretinal fluid. Such relation can shed light on pathophysiological disease mechanisms and constitute a biomarker for disease activity.
Chronic CSC - The proposed study tests the hypothesis that choroidal blood flow characteristics will change in response to standard treatment with PDT. The research of such changes will increase the understanding of the treatment response. This knowledge will help in the effort to understand the why some patients are non-responsive to the treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Acute | Patients with acute first attack CSC with subretinal fluid (SRF) on OCT and symptom duration under 4 months. | ||
| Chronic | Patients with chronic CSC, i.e. symptoms and SRF for more than 4 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Verteporfin | Drug | Chronic CSC are receiving one treatment before the observation period. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in mean blur rate | Relative changes in choroidal blood flow | 6 months |
| Change in pulse wave form analysis | Changes in the shapes of pulse curves | 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in choroidal density | Changes in the tissue density | 6 months |
| Change in choroidal thickness | Changes in the morphology of the choroid |
Not provided
Inclusion Criteria:-
Able to sign informed consent
Possible to obtain fundus imaging
Acute CSC ˂4 months of duration in one eye, defined as:
b) Patient history and examination consistent with acute CSC c) Characteristic appearance of acute CSC on fundus autofluorescence (FAF) and OCT
Chronic CSC ≥4 months of duration in one eye, defined as:
Exclusion Criteria:
Not provided
Not provided
Patients diagnosed with acute or chronic CSC.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Vegard Forsaa, MD PhD | Contact | +4748152212 | forsaa@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Vegard Forsaa, MD PhD | Helse Stavanger HF | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stavanger University Hospital, Department of Ophthalmology | Recruiting | Stavanger | 4016 | Norway |
This study can be expanded as a multicenterstudy. I so, IPD will be shared among the study group.
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D056833 | Central Serous Chorioretinopathy |
| ID | Term |
|---|---|
| D012164 | Retinal Diseases |
| D005128 | Eye Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077362 | Verteporfin |
| ID | Term |
|---|---|
| D011166 | Porphyrins |
| D045725 | Tetrapyrroles |
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 |
Not provided
Not provided
Not provided
Not provided
Not provided
| 6 months |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |